Aldeyra Therapeutics (NASDAQ:ALDX) Posts Quarterly Earnings Results, Misses Estimates By $0.30 EPS

Aldeyra Therapeutics (NASDAQ:ALDX) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30), Zacks reports.

Aldeyra Therapeutics Trading Down 19.4 %

Shares of Aldeyra Therapeutics stock traded down $1.23 during trading hours on Friday, reaching $5.11. The stock had a trading volume of 1,822,545 shares, compared to its average volume of 397,867. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.92. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average is $5.48 and its 200 day moving average is $5.38.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.